All Cases

Indication And Portfolio Prioritization

Disease area factbook creation for a peri-launch Hem-Onc asset

Prioritization of tumor types for a tumor agnostic oncology asset to focus promotional efforts

Evaluated Ischemic Heart Failure Commercial Opportunity to Guide Portfolio Investment Decisions at a Mid-Size Biotech

Indication prioritization for an early-stage oncology asset

Defined business unit and opportunity prioritization to expand the Brain Cancer portfolio of a large manufacturer

Evaluated 10 potential indications for a clinical-stage Biotech seeking to prioritize the clinical path to market and potential return of two assets

Glaucoma Portfolio Optimization for a Large Pharmaceutical Company to Unlock Brand Synergies After Recent Acquisitions

Assessment of a novel Ophthalmology research platform to prioritize investment in potential pipeline indications

Portfolio assessment for a leading, clinical-stage Ophthalmology Biotech to understand portfolio planning implications of a dynamic marketplace

Lifecycle management and portfolio planning in pain-related diseases to prioritize time/resource and investment